Drug Profile


Alternative Names: BVAC C

Latest Information Update: 11 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cellid Company
  • Class Vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Cervical cancer

Most Recent Events

  • 01 Oct 2016 Phase-I clinical trials in Cervical cancer (Metastatic disease, Second-line therapy or greater) in South Korea (IV) (NCT02866006)
  • 09 Aug 2016 Preclinical trials in Cervical cancer in South Korea (IV) before August 2016
  • 09 Aug 2016 Cellid plans a phase I trial for Cervical cancer (Recurrent, Metastatic, Second line therapy or greater) in South Korea (NCT02866006)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top